CN Bio, an Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), has announced a research collaboration with the Infection Innovation Consortium (iiCON), a global collaborative infectious disease R&D program, to validate the next generation of COVID-19 research tools.   iiCON’s £174 million ($234.99 million) program brings together industry, academia, and clinicians to accelerate the discovery, development and deployment of new ...